Inceptionr LLC Makes New $1.22 Million Investment in Zimmer Biomet Holdings, Inc. $ZBH

Inceptionr LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the third quarter, Holdings Channel.com reports. The fund bought 12,359 shares of the medical equipment provider’s stock, valued at approximately $1,217,000.

A number of other hedge funds have also modified their holdings of the business. Vanguard Group Inc. boosted its position in Zimmer Biomet by 0.9% during the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock worth $2,120,751,000 after acquiring an additional 198,370 shares during the last quarter. Dodge & Cox raised its holdings in Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after acquiring an additional 2,533,009 shares during the last quarter. American Century Companies Inc. lifted its stake in Zimmer Biomet by 8.7% in the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after purchasing an additional 458,903 shares in the last quarter. Geode Capital Management LLC lifted its stake in Zimmer Biomet by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock worth $465,480,000 after purchasing an additional 69,485 shares in the last quarter. Finally, Primecap Management Co. CA boosted its holdings in shares of Zimmer Biomet by 0.6% during the 2nd quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock worth $429,675,000 after purchasing an additional 27,860 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Stock Up 0.7%

ZBH stock opened at $94.08 on Monday. Zimmer Biomet Holdings, Inc. has a one year low of $84.59 and a one year high of $114.44. The firm has a market cap of $18.41 billion, a PE ratio of 26.58, a PEG ratio of 1.92 and a beta of 0.58. The firm’s 50 day moving average price is $92.13 and its 200-day moving average price is $95.60. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. The company had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, equities research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, April 30th. Stockholders of record on Tuesday, March 31st will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 27.12%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on ZBH shares. TD Cowen upgraded Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. Evercore raised Zimmer Biomet from an “in-line” rating to an “outperform” rating and boosted their price objective for the stock from $94.00 to $120.00 in a research note on Monday, January 5th. William Blair initiated coverage on Zimmer Biomet in a report on Friday, February 20th. They issued a “market perform” rating for the company. Canaccord Genuity Group cut their target price on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Finally, Weiss Ratings reissued a “hold (c-)” rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have issued a Hold rating and three have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.